Last reviewed · How we verify
NCT04485975
Therapeutic Plasma Exchange in Thyrotoxicosis
trial testing Therapeutic plasma exchange in Thyrotoxicosis in 27 participants. Completed in 1 April 2020.
1 February 2019
Quick facts
| Lead sponsor | Baskent University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 27 |
| Start date | 1 January 1999 |
| Primary completion | 1 February 2019 |
| Estimated completion | 1 April 2020 |
Drugs / interventions tested
- Therapeutic plasma exchange — full drug profile →
Conditions studied
- Thyrotoxicosis — all drugs for Thyrotoxicosis →
Sponsor
Baskent University
Who can join
18 and older, any sex, with Thyrotoxicosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Therapeutic plasma exchange (TPE) is indicated in cases where antithyroid medications cannot be used due to the side effects or attain no adequate hormonal suppression response at the highest dosage and in cases of rapid onset of clinical symptoms. This study presents the treatment results of patients who underwent TPE and subsequently operated for thyrotoxicosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04485975
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Therapeutic plasma exchange
Trials testing the same drug.
- NCT05182515 — Plasma Exchange in Covid-19 Patients With Anti-interferon Autoantibodies · Phase 3 · unknown
- NCT04057872 — Therapeutic Plasma Exchange in Adult Patients With Severe Sepsis · Phase 1 · completed
- NCT04592705 — Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalize · Phase 1 · unknown
- NCT04973488 — Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients · NA · completed
- NCT04685655 — RescuE pLAsma eXchange in Severe COVID-19 · NA · terminated
Other Baskent University trials
Trials by the same sponsor.
- NCT07521982 — Comparison of Frailty, Physical Fitness Parameters, and Irisin Levels Between Patients With Multiple Sclerosis and Healt · not yet recruiting
- NCT07202650 — THE EFFECT OF GUİDED IMAGERY ON PREMENSTRUAL SYNDROME · NA · recruiting
- NCT07394907 — The Effectiveness of Gamified Metaverse-Based Training on Patient Safety for Nursing Students · NA · not yet recruiting
- NCT07395284 — The Effect of Gamified Metaverse-Based Training on Nursing Students' Self-Efficacy and Metaverse Perception Regarding Pr · NA · not yet recruiting
- NCT07385339 — Comfort Communication Model Intervention for Burn Pain and Pain Anxiety · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04485975 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baskent University
- Last refreshed: 24 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04485975.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing